Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish Multicenter Trandolapril Study

We studied the effect of trandolapril 2 mg once-daily on mild-to-moderate essential hypertension in 325 overweight patients in an open-label, prospective, multicenter study. The male patients had a body mass index >25.5 kg/m(2), and the females >24 kg/m(2). Mild-to-moderate hypertension was defined as a baseline diastolic blood pressure (DBP) of 90 to 110 mm Hg. After a washout period of 2 weeks, patients were treated for 4 weeks. Efficacy analysis was performed on 295 patients. Mean systolic blood pressure (SEP) and DBP fell significantly from 155.7 +/- 16.7/95.8 +/- 8.8 mm Hg to 136.8 +/- 15.9/82.9 +/- 8.0 mm Hg at the end of treatment. The mean reductions in SEP and DBP were 20 mm Hg and 13 mm Hg, respectively. The target blood pressure (DBP <90 mm Hg and a reduction of at least 5 mm Hg) was achieved in 254 (86%) of 295 patients. There was a slight, statistically significant reduction in heart rate after drug therapy. Serum total cholesterol concentrations fell significantly from 216.5 +/- 40.5 mg/dL to 213.7 +/- 40.2 mg/dL, and low-density-lipoprotein cholesterol from 141.7 +/- 39.9 mg/dL to 138.3 +/- 39.4 mg/dL at the end of the trial. No other clinically important changes in hematologic or biochemical variables of clinical importance occurred. The overall incidence of adverse events was 9.6% and included headache in 9 patients, cough in 7, and dizziness in 6. Four patients (1.3%) withdrew from the study because of side effects, but the effects were transient and did not require treatment. We conclude that trandolapril is effective and safe for overweight patients with mild-to-moderate essential hypertension

Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial

Background: Only 40% to 60% of patients with essential hypertension respond adequately to antihypertensive monotherapy. The combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, both of which have tissue-protective properties but different mechanisms of action, may lead to an additive antihypertensive effect

Acute myocardial infarction due to chemotherapy in a patient with testis tumor

A 26-year-old male patient was admitted to our clinic due to precordial pain, sweating, nausea and vomiting. Electrocardiogram and cardiac enzymes were consistent with an acute myocardial infarction (AMI). The patient had a history of 2 courses of chemotherapy (cisplatin + etoposide + bleomycin) upon detection of testis tumor (seminoma) on the last day of which he had symptoms of AMI. Acute myocardial infarction was accepted to be caused by cisplatin and etoposide. Since AMI due to chemotherapy is a very rare complication, it is decided to report this case

Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS)

Objective-A multicentre, double-blind comparative study was performed to compare the effects of trimetazidine with diltiazem on exercise performance in patients with stable angina pectoris